|
Mar 17
|
30 Biggest Biotechnology Companies in the World
|
|
Mar 13
|
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
|
|
Mar 11
|
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
|
|
Mar 8
|
10 Biotech Stocks with Huge Potential
|
|
Mar 8
|
2 Biotech Stocks to Buy Hand Over Fist in March
|
|
Mar 7
|
Why Is Exelixis (EXEL) Up 10.9% Since Last Earnings Report?
|
|
Mar 7
|
10 Mid-Cap Stocks with Insider Purchases
|
|
Mar 6
|
EXEL vs. REGN: Which Stock Is the Better Value Option?
|
|
Jan 30
|
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jan 29
|
Here's Why Exelixis (EXEL) is a Strong Value Stock
|
|
Jan 25
|
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
|
|
Jan 11
|
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
|
|
Jan 11
|
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
|
|
Jan 9
|
Cytek Biosciences, Inc. (CTKB) Surges 10.3%: Is This an Indication of Further Gains?
|
|
Dec 19
|
11 Stocks Insiders and Billionaires Are Crazy About
|
|
Dec 8
|
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?
|
|
Dec 7
|
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
|
|
Dec 7
|
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
|
|
Dec 5
|
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
|
|
Dec 4
|
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
|